AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma.
Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE.
Fukuda K, et al. Among authors: riding rl.
J Exp Med. 2021 Sep 6;218(9):e20200962. doi: 10.1084/jem.20200962. Epub 2021 Jul 29.
J Exp Med. 2021.
PMID: 34325468
Free PMC article.